200 related articles for article (PubMed ID: 28574274)
1. Practical considerations for cangrelor use in patients with acute coronary syndromes.
Leonardi S; Bhatt DL
Eur Heart J Acute Cardiovasc Care; 2019 Feb; 8(1):39-44. PubMed ID: 28574274
[TBL] [Abstract][Full Text] [Related]
2. Cangrelor: A New Route for P2Y12 Inhibition.
Sible AM; Nawarskas JJ
Cardiol Rev; 2017; 25(3):133-139. PubMed ID: 28379902
[TBL] [Abstract][Full Text] [Related]
3. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Capodanno D; Milluzzo RP; Angiolillo DJ
Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
[TBL] [Abstract][Full Text] [Related]
4. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
Price MJ
Interv Cardiol Clin; 2017 Jan; 6(1):39-47. PubMed ID: 27886821
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural platelet inhibition with cangrelor in P2Y
Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
[TBL] [Abstract][Full Text] [Related]
6. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
7. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
8. Cangrelor: a review on pharmacology and clinical trial development.
Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
[TBL] [Abstract][Full Text] [Related]
9. Why we need intravenous antiplatelet agents.
Tyler JM; Burris RJ; Seto AH
Future Cardiol; 2016 Sep; 12(5):553-61. PubMed ID: 27255111
[TBL] [Abstract][Full Text] [Related]
10. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
[TBL] [Abstract][Full Text] [Related]
11. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
13. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Alexopoulos D; Pappas C; Sfantou D; Lekakis J
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
[TBL] [Abstract][Full Text] [Related]
14. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
15. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.
Badreldin HA; Carter D; Cook BM; Qamar A; Vaduganathan M; Bhatt DL
Am J Cardiol; 2017 Aug; 120(3):359-361. PubMed ID: 28576266
[TBL] [Abstract][Full Text] [Related]
17. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Bowman S; Gass J; Weeks P
Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
[TBL] [Abstract][Full Text] [Related]
20. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.
Kubica J; Adamski P; Dobrzycki S; Gajda R; Gąsior M; Gierlotka M; Jaguszewski M; Legutko J; Lesiak M; Navarese EP; Niezgoda P; Ostrowska M; Pawłowski T; Tycińska A; Umińska JM; Witkowski A; Gil R
Cardiol J; 2024; 31(1):133-146. PubMed ID: 37964649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
